Clinical Research Study for People with Symptomatic Heart Failure

Today, over 26 million people worldwide suffer from heart failure (HF).1 Although medications are available to help manage the effects of HF, many patients continue to experience symptoms. People with heart failure have difficulty breathing, often struggle with daily activities, are frequently hospitalized, and have a poor quality of life.

A new non-surgical treatment, called interatrial shunting, is now available through the REDUCE LAP-HF IV clinical study. This study was recently authorized by the Food and Drug Administration (FDA) for enrollment in the United States. The study is evaluating the Corvia Atrial Shunt therapy to improve quality of life and reduce HF-related symptoms and hospitalizations for people with heart failure.

Like the 1000+ patients enrolled in previous Corvia Atrial Shunt studies, you may be a candidate for the REDUCE LAP-HF IV study if you have symptomatic heart failure.